Mankind Pharma Acquires Majority Stake in Armed Cell Therapeutics

Company Mankind Pharma; Armed Cell Therapeutics Event Type Majority Equity Investment (70% stake) Modality CAR-T cell therapy; multi-targeting and armored constructs; potential in vivo CAR-T Asset Preclinical multi-targeting and armed CAR-T portfolio (codes undisclosed) Target Undisclosed Disease Area Non-Hodgkin lymphoma; small-cell lung cancer Summary Mankind…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Agenus Raises Up to $340M on Neoadjuvant MSS Colon Cancer
Infinimmune Raises $75 Million for Two Atopic-Dermatitis Antibodies
GenScript Raises HK$2.33 Billion for AIDD Expansion
TriGemX Raises $94 Million for Phase 3 Migraine Trials